By A Mystery Man Writer
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
Cancer Support Groups, Counseling, Education & Financial Assistance
Oncology Times, February 10 2016 Vol.38 Issue 3
Current Oncology, Free Full-Text
Home Current Oncology Reports
Free PQRS Reporting Now Available Through QOPI, No Additional
First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF
Current Oncology, Free Full-Text
Oncology Board Review: Blueprint Study Guide and Q&A (3rd Revised edition) by Francis P. Worden
Journal of Clinical Oncology
Journal of Current Oncology - Free full text articles from Journal of Current Oncology
Current Oncology, Free Full-Text
Home page Cancer Cell International
ECU Health to offer free screenings for prostate cancer in